Rare Disease Report

Early Use of Jakafi in Myelofibrosis Beneficial

DECEMBER 05, 2016
Srdan Verstovsek, MD, PhD

Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston Texas talked to us about the recent data he presented at the 58th Annual ASH Meeting & Exposition showing the long term efficacy of jakafi (ruxolitinib) in patients with myelofibrosis.


Verstovsek S, Gupta V, Gotlib J, et al. A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). Presented at the 58th Annual ASH Meeting and Exposition; San Diego, CA; December 3-6, 2016. Abstract 3110.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.